Analysis of drug interactions.

[1]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[2]  E. Giovannetti,et al.  Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells , 2008, Molecular Pharmacology.

[3]  G. Peters,et al.  Basis for effective combination cancer chemotherapy with antimetabolites. , 2000, Pharmacology & therapeutics.

[4]  I. Cree,et al.  ATP-based tumor chemosensitivity testing: assisting new agent development. , 1999, Anti-cancer drugs.

[5]  G. Peters,et al.  Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. , 1999, Anti-cancer drugs.

[6]  N. Saijo,et al.  In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. , 1997, Seminars in oncology.

[7]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[8]  G. Peters,et al.  Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. , 1991, European journal of cancer.

[9]  Berenbaum Mc.  What is synergy? , 1989, Pharmacological reviews.

[10]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. , 1954, The Journal of biological chemistry.

[11]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[12]  G. Steel,et al.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. , 1979, International journal of radiation oncology, biology, physics.